KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS mutation + STK11 mutation	Lung Adenocarcinoma	KRAS mutation + STK11 mutation	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D
KRAS mutation + STK11 mutation	Lung Adenocarcinoma	KRAS mutation + STK11 mutation	Lung Adenocarcinoma	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D

KRAS mutation + STK11 mutation

Associations